Certain Warrants of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021.
July 22, 2021
Share
Certain Warrants of Second Sight Medical Products, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2021. These Warrants will be under lockup for 31 days starting from 22-JUN-2021 to 23-JUL-2021.
Details:
The company's directors and officers have agreed for a period of 30 days after the date of this prospectus supplement, without the prior written consent of the representative, not to directly or indirectly issue, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of any shares of common stock or other capital stock or any securities convertible into or exercisable or exchangeable for common stock or other capital stock; or file or cause the filing of any registration statement under the Securities Act with respect to any shares of common stock or other capital stock or any securities convertible into or exercisable or exchangeable for common stock or other capital stock; or complete any offering of debt securities of the Company, other than entering into a line of credit, term loan arrangement or other debt instrument with a traditional bank; or enter into any swap or other agreement, arrangement, hedge or transaction that transfers to another, in whole or in part, directly or indirectly, any of the economic consequences of ownership of common stock or other capital stock or any securities convertible into or exercisable or exchangeable for common stock or other capital stock, whether any transaction described in any of the foregoing bullet points is to be settled by delivery of common stock or other capital stock, other securities, in cash or otherwise, or publicly announce an intention to do any of the foregoing.
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing implantable visual prosthetics devices that restore vision to blind individuals. The Company manufactures neuromodulation devices for blindness and engaged in developing new technologies to treat sight-impaired individuals. Its approved product, the Argus II Retinal Prosthesis System (Argus II), treats outer retinal degenerations, such as retinitis pigmentosa (RP). It is engaged in developing the Orion Visual Cortical Prosthesis System (Orion), an implanted cortical stimulation device, which provides artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease and eye injury. Orion works by converting video images captured by a miniature camera housed in a user's glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes.